Company received prestigious Fast Company innovation recognition, achieved $1.1M in first-year commercial revenue with growing adoption at major cancer centers, Phase III trial progressing on schedule, and has significant market opportunity ($400M+ initial TAM expanding to multi-billion potential). Multiple positive commercial and clinical milestones demonstrate strong momentum.
Also mentions RNXT
Articles that tag RNXT but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
